

1 Running title: Dietary salicylate and CRS

2 Type of article: Original Contribution

3 Exploring the association between ingestion of foods with
4 higher potential salicylate content and symptom exacerbation
5 in chronic rhinosinusitis
6 Data from the National Chronic Rhinosinusitis Epidemiology
7 Study

8 Professor Carl M Philpott^{1,2}, Dr Rupert Smith^{1,2}, Mr Cameron R Davies-Husband^{2,3}, Miss Sally Erskine¹,
9 Dr Allan Clark¹, Professor Ailsa Welch¹, Professor Claire Hopkins⁴, Mr Sean Carrie⁵, Professor Jaydip
10 Ray⁶, Mr Vishnu Sunkaraneni⁷, Mr Naveed Kara⁸, Professor Nirmal Kumar⁹, Mr Alasdair Robertson¹⁰,
11 Mr Shahram Anari¹¹, Mr Robert Almeyda¹², Professor Andrew Wilson¹,

12 ¹Norwich Medical School, University of East Anglia, Norfolk NR4 7TJ, United Kingdom

13 ²James Paget University Hospital NHS Foundation Trust, Gorleston, United Kingdom

14 ³Royal Sussex County Hospital, Surrey, United Kingdom

15 ⁴Guys & St Thomas' Hospital, London, United Kingdom

16 ⁵Freeman Hospital, Newcastle, United Kingdom

17 ⁶Sheffield University Teaching Hospitals, Sheffield, United Kingdom

18 ⁷Royal Surrey County Hospital, Guildford, United Kingdom

19 ⁸Darlington Memorial Hospital, United Kingdom

20 ⁹Wrightington, Wigan & Leigh NHS Foundation Trust, United Kingdom

21 ¹⁰Southern General Hospital, Glasgow, United Kingdom

22 ¹¹Birmingham Heartlands Hospital, Birmingham, United Kingdom

23 ¹²Royal Berkshire Hospital, Reading, United Kingdom

24
25 *On behalf of the CRES group:*

26 Chief Investigator: Prof Carl Philpott, Professor of Rhinology & Olfactology at University of East Anglia and Honorary Consultant ENT Surgeon, James Paget
27 University Hospital.

28 Prof Carl Philpott^{1*}, Miss Sally Erskine¹, Dr Allan Clark^{*}, Prof Claire Hopkins², Mr Alasdair Robertson⁴, Mr Shahzada Ahmed⁶, Mr Naveed Kara¹², Mr
29 Sean Carrie¹¹, Mr Vishnu Sunkaraneni²⁰, Prof Jaydip Ray¹⁷, Mr Shahram Anari⁷, Mr Paul Jervis¹⁰, Miss Jaan Panesaar¹⁸, Mr Amir Farboud⁵, Prof Nirmal
30 Kumar³, Mr Russell Cathcart⁸, Mr Robert Almeyda¹⁴, Prof Hisham Khalil⁹, Mr Peter Prinsley¹³, Mr Nicolas Mansell¹⁵, Mr Mahmoud Salam¹⁶, Mr Jonathan
31 Hobson¹⁹, Ms Jane Woods¹, Dr Emma Coombes^{*}.

32 ¹James Paget University Hospital NHS Foundation Trust, Gorleston, ²Guys & St Thomas' Hospital, London, ³Wrightington, Wigan & Leigh NHS Foundation
33 Trust, ⁴Southern General Hospital, Glasgow, ⁵Wrexham Maelor Hospital, Wales, ⁶University Hospitals Birmingham, ⁷Heart of England NHS Foundation
34 Trust, Birmingham, ⁸Cumberland Infirmary, Carlisle, ⁹Derriford Hospital, Plymouth, ¹⁰Northampton General Hospital, ¹¹Freeman Hospital, Newcastle,
35 ¹²Sunderland Royal Infirmary, ¹³Norfolk & Norwich University Hospital, ¹⁴Oxford University Hospitals, ¹⁵Royal Berkshire NHS Foundation Trust, Reading,
36 ¹⁶The Ipswich Hospital, ¹⁷Sheffield Teaching Hospitals, ¹⁸Luton & Dunstable Hospital, ¹⁹Warrington and Halton Hospitals NHS Foundation Trust, ²⁰Royal
37 Surrey County Hospital, Guildford, ^{*}Norwich Medical School, University of East Anglia, Norfolk NR4 7TJ, United Kingdom, [§]Spire Norwich Hospital.

38 NIHR portfolio ID: 12926; **Funding: The Anthony Long Trust, the Bernice Bibby Trust.**

39 ***E-mail for correspondence: C.Philpott@uea.ac.uk***

40
41 *This study has been reported in accordance with the STROBE statement guidelines for the*
42 *reporting of observational studies.*

43
44 **Word count = 3009**

45 Abstract

46

47 **Introduction:** Pharmacological salicylates are known to trigger respiratory exacerbations in
48 patients with Non-Steroidal Exacerbated Respiratory Disease (N-ERD), a specific phenotype
49 of Chronic Rhinosinusitis (CRS) and asthma. The impact of dietary sources of salicylates
50 across subgroups of CRS is not well understood. The hypothesis is that in patients with
51 nasal polyps present, there is likely to be a higher incidence of symptom exacerbation due to
52 dietary salicylates regardless of any known response to pharmacological salicylate.

53 **Methods:** The Chronic Rhinosinusitis Epidemiology Study (CRES) was a questionnaire-
54 based case-control study which sought to characterise the UK CRS population in terms of
55 sociological, economic and medical factors. Using specific questions to examine participant
56 responses relating to symptom exacerbation from food groups thought to be high in
57 salicylate content, this analysis of the CRES database sought to compare an estimate of the
58 prevalence of dietary sensitivity due to food with higher potential salicylate content across
59 patients with CRS with (CRSwNPs) and without nasal polyposis (CRSsNPs) and with allergic
60 fungal rhinosinusitis (AFRS).

61 **Results:** The CRSwNPs group were significantly more likely than controls to report
62 symptom exacerbation due to ingestion of food groups with higher potential dietary salicylate
63 content (OR 3.16, 95% CI 1.78 – 5.61, $p < 0.001$). The same trend was observed amongst
64 CRSsNPs participants to a lesser degree (OR 2.03, 95% CI 1.15 – 3.58, $p = 0.01$). Reported
65 response to the individual specific food groups wine, nuts, spicy foods, fruit and vegetables
66 demonstrated that a statistically significant proportion of CRSwNPs and AFRS participants
67 reported sensitivity to wine (Controls 0.9%, CRSwNPs 18.4%, AFRS 44.0%, $p < 0.008$).

68 **Conclusions:** This analysis suggests that there is an association between symptom
69 exacerbation in response to food products with higher potential salicylate content,
70 specifically wine, in CRS patients both with and without nasal polyposis when compared to

71 controls, but especially in the CRSwNPs and AFRS phenotypes. Further studies are needed
72 to detail if this relationship represents a causal relationship to dietary salicylate. The data
73 present the possibility that a wider group of CRS patients may elicit salicylate sensitivity than
74 those with known N-ERD.

75

76 Key words: rhinosinusitis, salicylate, asthma, aspirin exacerbated respiratory disease

77 Introduction

78 Salicylic acid is a phenolic phytohormone found in plants, with roles in growth and
79 development, photosynthesis, transpiration, ion uptake and transport. Salicylic acid also
80 induces specific changes in leaf anatomy and chloroplast structure, and is involved in
81 endogenous signaling, thereby mediating plant defence against pathogens ¹. Salicylates are
82 commonly found in a wide variety of foods, with unripe fruit and vegetables, spices, nuts and
83 seeds thought to be particularly high in content. Assessments of daily consumption of
84 salicylate vary, with a recent study in a Scottish population estimating daily intake to be
85 4.42mg/day for males and 3.16mg/day for females ².

86 Formerly known as Samter's Triad and AERD, Non-Steroidal Exacerbated Respiratory
87 Disease (N-ERD) is characterised by the coexistence of asthma, eosinophilic rhinosinusitis
88 and nasal polyposis, with respiratory exacerbations triggered by ingestion of aspirin
89 (acetylsalicylic acid) or other non-steroidal anti-inflammatory medications (NSAIDs) ^{3, 4}. N-
90 ERD forms a subgroup of asthma and/or chronic rhinosinusitis (CRS) which is often
91 refractory to commonly used medical and surgical therapies. N-ERD is thought to affect 16%
92 of patients with the subtype of CRS with nasal polyposis (CRSwNPs) ⁵. A low-salicylate diet
93 has been touted as a possible adjunct in the management of patients with N-ERD ⁶. Whilst
94 the impact of dietary salicylates in N-ERD is well recognised in the literature, little is known
95 about the prevalence of dietary salicylate sensitivity across other phenotypes of CRS. The
96 CRES dataset presented an opportunity to examine the prevalence of possible dietary
97 salicylate sensitivity in all CRS patients regardless of their phenotype and any prior
98 diagnosis of aspirin sensitivity.

99 Objectives

100 The Chronic Rhinosinusitis Epidemiology Study (CRES) was primarily designed to
101 distinguish differences in socio-economic status, geography, medical/psychiatric co-
102 morbidity, lifestyle and overall quality of life between patients with CRS and healthy controls,

103 however patient-reported sensitivities to various foodstuffs were also captured as part of the
104 study-specific questions. The specific aim of *this* analysis of the CRES database was to
105 compare the prevalence of potential higher dietary salicylate sensitivity across CRS
106 phenotypes (irrespective of prior diagnosis of N-ERD) and compared to controls and
107 characterise any differences between them. This will help to inform ENT surgeons and
108 respiratory physicians of the potential role of avoidance of dietary salicylates in CRS
109 patients' symptom control.

110 Methods

111 The study was sponsored by the University of East Anglia (UEA) and funded by the Anthony
112 Long and Bernice Bibby Trusts. Ethical approval was granted by the Oxford C Research
113 Ethics Committee (Ref: 07/H0606/100).

114 Study Design

115 The CRES was a prospective, questionnaire-based, case-control study conducted between
116 October 2007 and September 2013 at 30 tertiary/secondary care sites across the United
117 Kingdom. Patients with CRS and healthy control subjects were asked to complete a single,
118 study-specific questionnaire, capturing a variety of demographic and socio-economic
119 variables, environmental exposures and medical co-morbidities (See appendix 1).

120 Participants and Data Sources

121 Prospective participants were identified for recruitment at ENT outpatient clinics at 30
122 participating centres. Patients with CRS were examined by a clinician and classified by
123 subgroup of CRS (CRSwNPs, CRSsNPs or AFRS) as per EPOS criteria (see below).
124 Healthy controls were recruited from family members of patients attending ENT clinic, and
125 from members of hospital staff at recruitment sites.

126 Questionnaires were completed during the clinic visit or taken home to be completed and
127 returned by prepaid post. No participant identifiable data was captured therefore consent
128 was not required by the ethics committee who stated that this was implied through return of

129 the questionnaire. Returned questionnaires were scanned and the data imported into in an
130 electronic database in Microsoft Excel. Records in the database were compared to physical
131 copies of the questionnaires by two members of the research team to ensure accuracy and
132 consistency between the two.

133 All CRS participants and healthy controls were required to meet the inclusion/exclusion
134 outlined below:

135 **CRS Participants**

136 *Inclusion Criteria*

137 Criteria for diagnosis of CRS with or without polyps (EPOS guidelines)⁷

138 At least two symptoms must be present for at least 12 weeks and include:

- 139 • One of either nasal blockage/obstruction/congestion and/or nasal discharge
140 (anterior/posterior nasal drip)
- 141 • and either facial pain/pressure and/or reduction or loss of sense of smell

142 and additionally:

- 143 • endoscopic signs of: polyps and/or mucopurulent discharge primarily from middle
144 meatus and/or; oedema/mucosal obstruction primarily in middle meatus
- 145 • and/or CT changes: mucosal changes within the ostiomeatal complex and/or sinuses

146 Patients were then classified as having chronic rhinosinusitis without polyps (CRSsNPs),
147 chronic rhinosinusitis with nasal polyps (CRSwNPs) or allergic fungal rhinosinusitis (AFRS);
148 patients with the latter additionally adhered to either the Bent and Kuhn criteria⁸ or the
149 modified Vancouver criteria⁹.

150

151 **Healthy Control Participants**

152 *Exclusion Criteria*

- 153 • Prior history of recurrent acute or chronic rhinosinusitis other than having had
154 previous common colds (acute viral rhinosinusitis).
- 155 • Any other nose/sinus disorders e.g allergic rhinitis (hayfever).
- 156 • Active medical problems that have required a hospital visit within the last 12 months.

157 *Exclusion Criteria for Both Groups*

- 158 • Patients/controls unable to comprehend written English.
- 159 • Patients/controls under the age of 18 years.

160

161 Quantitative Variables and Bias

162 Dietary questions were added as an amendment to the original questionnaire in 2012 on
163 recognition of the need to ask specific questions related to diet. Questions exploring
164 potential dietary salicylate sensitivity asked *“Have you ever experienced any allergy
165 symptoms such as wheezing, runny nose, or itchy skin when taking any of the following?”*
166 with a simple Yes/No checkbox for the response. The question was intentionally phrased to
167 focus on respiratory/nasal exacerbations characterised by itching, wheezing and
168 rhinorrhoea, in order that those with common gastrointestinal intolerance would not answer
169 “yes” for the purposes of this questionnaire. Food groups included in the questionnaire were
170 chosen to cover a broad range of foods believed to have a high level of salicylate content
171 (table 1). Participants reporting a “yes” to any of the dietary questions were therefore
172 considered to have self-reported exacerbation of symptoms in response to foods of potential
173 high salicylate content.

174 At the top of the list of food items, aspirin was also listed as an option to consider. For
175 participants who also reported sensitivity to aspirin and also reported asthma as well as
176 being diagnosed with CRSwNPs, were considered to have N-ERD for the purpose of this
177 analysis; a more detailed analysis of asthma, N-ERD and inhalant allergy is reported
178 elsewhere¹⁰.

179 Sample Size Calculation

180 Since this is a secondary analysis of an existing database, a power calculation was not
181 performed for this specific analysis. The sample size calculation was based on the primary
182 outcome of the study which was to look for common associations between socioeconomic
183 factors and CRS. In order for the study to have 80% power to detect a difference of 10% in
184 “low social class” between controls and CRS participants, assuming a 30% rate in the CRS
185 participants, with approximately 5 CRS participants to 1 control patient, 965 CRS
186 participants and 193 controls were required¹¹.

187 Statistical Methods

188 All statistical analyses were conducted using IBM SPSS statistics v22. Proportions of CRS
189 sub-groups reporting sensitivities to different food groups were compared by Chi-squared
190 test or Fisher's exact test where appropriate. A Bonferroni correction was applied to correct
191 for multiple testing (0.05/6) (6 main groups of foods), resulting in $p < 0.008$ being considered
192 statistically significant. Odds ratios were calculated for main food groups and individual food
193 groups by binary logistic regression and adjusted for potential confounding variables. For the
194 purposes of regression, the AFRS group was merged with the CRSwNPs group due to the
195 small sample size of the former.

196 Results

197 Study Participants

198 A total of 1535 questionnaires were returned with 1470 considered eligible for inclusion after
199 removal of duplicates and questionnaires with missing data (see figure 1). However,
200 questions relating to diet and allergy were added part way through the recruitment period.
201 This analysis is therefore based on the 873 participants who completed the updated version
202 of the questionnaire that included the dietary questions. The overall response rate of those
203 identified to take part in the study was 66% of those distributed for the entire study.

204 Descriptive Data

205 Of the 873 participants, 402 (46.0%) were CRSwNPs, 336 (38.5%) CRSsNPs, 25 (2.9%)
206 AFRS and 110 (12.6%) controls. The demographic characteristics of each group are
207 demonstrated in table 2. Controls were generally younger than CRS participants and had a
208 greater proportion of females. Cases and controls were broadly similar in having a majority
209 proportion of White British participants. The CRSwNPs and AFRS groups had a greater
210 proportion of participants with asthma (52.5% and 68.0% respectively) and sensitivity to
211 aspirin (10.4% and 44.0%). 9.9% (40 participants) of the CRSwNPs group and 40% (10
212 participants) of the AFRS group reported both asthma and sensitivity to aspirin as defined
213 above. Amongst this subset of participants with concurrent asthma and aspirin sensitivity, a

214 comparable proportion of the CRSwNPs group and AFRS group also reported sensitivity to
215 one or more of the food groups (65.0% and 60% respectively – see figure 2).

216 Primary Outcome Data and Main Results

217 Participants with nasal polyps (including both those with CRSwNPs and AFRS) were most
218 likely to report symptom exacerbation to one or more of the food groups included in the
219 questionnaire when compared with controls. However, a breakdown of the analysis to
220 specific food groups determined that of all possible paired combinations of controls,
221 CRSwNPs and AFRS showed statistically significant variation in the proportion of
222 participants reporting sensitivity to wine (Controls 0.9%, CRSwNPs 18.4%, AFRS 44.0%,
223 $p<0.001$), as demonstrated in figure 3. Participants with AFRS also reported significantly
224 more reactions to nuts than controls (16.0% vs 0%, $p=0.001$). Although several other pairs
225 were found to be significant at the $p<0.05$ level (Fruit; Controls vs CRSwNPs $p=0.04$,
226 Controls vs AFRS $p=0.02$, Vegetables; Controls vs AFRS $p=0.03$, CRSwNPs vs AFRS
227 $p=0.01$, CRSsNPs vs AFRS $p=0.04$), these associations were not found to be statistically
228 significant after the Bonferroni correction was applied.

229 After adjusting for potential confounders including age, sex, and aspirin sensitivity, the
230 association between foods with higher potential dietary salicylate and symptom exacerbation
231 was enhanced (adjusted OR 3.16, 95% CI 1.78 – 5.61, $p<0.001$), as demonstrated in table
232 3; the adjustment accounted for differences in the subgroup demographics¹¹. The CRSsNPs
233 group were also found to be more likely to report sensitivity than controls (adjusted OR 2.03,
234 95% CI 1.15 – 3.58, $p=0.01$), although to a lesser degree than the group with nasal
235 polyposis. Separately, 56% ($n=14$) of the AFRS group reported symptom exacerbation,
236 although this group was not included individually in the regression analysis due to the small
237 sample size of 25 participants. A further analysis to remove participants who reported
238 autoimmune disorders, ciliary dyskinesias and immunodeficiencies, did not change the
239 associations reported above (table 3a).

240 Discussion

241 The Chronic Rhinosinusitis Epidemiology Study is the largest epidemiological study of CRS
242 in the UK to date and is believed to be the first study to collect data on patient reported
243 symptom exacerbation in response to ingestion of foods with higher potential salicylate
244 content in CRS subtypes other than the N-ERD subgroup. Other studies investigating
245 sensitivity to foodstuffs in CRS subgroups have focused on non-specific food sensitisation
246 and delayed food hypersensitivity measured by skin prick testing^{12, 13}.

247 Key Results

248 Within the CRES population we observed a significantly increased risk of reported symptom
249 exacerbation to wine in CRS participants both with and without nasal polyps when compared
250 to controls. The CRSwNPs group were 3 times more likely than controls to report these
251 responses. This likely reflects the inclusion of AFRS subjects in the test group and the fact
252 that almost 10% of the CRSwNPs group fulfilled the criteria for N-ERD. The proportion of
253 CRSwNPs participants suspected to have N-ERD in our study is lower than the 16%
254 observed by Stevens et al in a US population and may be a result of methodological
255 differences between the studies⁵.

256 The fact that the prevalence of reported symptom exacerbation to food products containing
257 potentially higher levels of salicylate is higher than patient reported aspirin sensitivity
258 amongst CRS participants in our study could suggest that some participants may also be
259 sensitive to aspirin but are unaware, although this relationship could be confounded by
260 respiratory sensitivity to other dietary components which commonly cause respiratory
261 symptoms such as sulphites¹⁴, which is true of wine where the biggest effect was seen.
262 Potential symptoms arising from sulphite ingestion includes dermatitis, urticaria, flushing,
263 hypotension, abdominal pain, diarrhoea, exacerbation of asthma and anaphylaxis. Sulphite
264 sensitivity is reported to be prevalent in 3 to 10% of asthmatic subjects who ingest them¹⁴.

265 In the CRES qualitative sub-study, Erskine et al determined that dietary factors were
266 frequently perceived to be a trigger for respiratory exacerbations, with wine being a specific
267 trigger highlighted by one participant¹⁵. Esmaeilzadeh et al used an oral food challenge test
268 in patients with CRSwNPs and found 69.9% of patients to be salicylate sensitive¹⁶.
269 Interestingly they reported red grape to be one of the most common foods inducing a
270 reaction. Our finding that CRS participants frequently reported sensitivity to wine also
271 suggests that grapes are a common trigger of sensitivity, but it is very possible that in some
272 participants this may be an effect of alcohol and/or sulphites as discussed above. There is
273 recent evidence to show the effect of alcohol on symptom exacerbation in CRSwNPs was
274 significantly more prevalent in patients suffering from recurrent disease and in patients with
275 severe symptomatology¹⁷.

276 Unlike aspirin sensitivity in the setting of N-ERD which is the result of abnormal arachidonic
277 acid metabolism causing inhibition of cyclooxygenase-1 (COX-1) and a subsequent
278 imbalance of inflammatory mediators¹⁸, non-acetylated salicylates of dietary origin have
279 been shown to selectively inhibit cyclooxygenase-2 (COX-2) gene expression¹⁹. COX-2 is
280 known to be down-regulated in the nasal polyps of patients with N-ERD²⁰⁻²². It is therefore
281 hypothesised that in addition to reactions to aspirin and other NSAIDs, patients with N-ERD
282 are also likely to experience sensitivity to dietary sources of salicylates. Interestingly the
283 CRSsNPs group in our study also demonstrated an increased risk of dietary salicylate
284 sensitivity compared to controls. This likely points to the fact that current
285 classification/phenotypic divisions of CRS do not necessarily reflect pathophysiological
286 subgroups for which true endotypes are yet to be fully determined.

287 Our data also appears to highlight an overlap between N-ERD and AFRS aetiopathogenic
288 factors, as over half of AFRS participants appear to report symptom exacerbation. Whilst the
289 small size of the AFRS group included in this study renders it difficult to draw definitive
290 conclusions, the fact that similar proportions of participants in the AFRS and CRSwNPs

291 groups with concurrent asthma and aspirin sensitivity (thereby suggestive of N-ERD) also
292 report symptom exacerbation to dietary salicylates, suggests there may be some
293 commonality between the two groups. We suggest that N-ERD should be considered in all
294 CRS patients who report symptom exacerbation in response to ingestion of food products
295 with higher potential dietary salicylate content, the implications being identification of a more
296 severe disease endotype, with early involvement of respiratory physicians where
297 appropriate. If indeed there is overlap between the pathophysiological disease mechanisms
298 of N-ERD and AFRS, aspirin desensitisation may be a potentially therapeutic option for the
299 latter; but at the very least, patients can be advised to avoid wine and possibly nuts in order
300 to prevent symptom exacerbations.

301 Interpretation

302 The interaction between diet and CRS is complex and poorly understood. A number of
303 special diets including a low salicylate diet have a theoretical basis for being able to
304 modulate the chronic inflammation seen in CRS, but the evidence for the clinical application
305 of dietary adjustment in management is lacking and is not recommended in national
306 guidelines²³. In a small randomized control crossover trial of 10 N-ERD patients, Sommer et
307 al investigated the use of the low salicylate diet as a management option in N-ERD and
308 observed an improvement in both subjective and objective outcome measures in patients
309 following the diet for a 6-week period⁶. The feasibility of implementing such a strategy as a
310 treatment adjunct was questioned in a recent update on the management of N-ERD which
311 highlighted the problem of long term adherence to the diet given the large number of
312 commonly eaten foods containing salicylates²⁴.

313 Limitations

314 Our results should be interpreted in the context of the limitations of the questionnaire-based
315 design of the study. Whilst positive responses to questions regarding reactions to foods
316 thought to be high in dietary salicylates are suggestive of potential symptom exacerbation,

317 only objective allergy testing or provocation tests could conclusively determine if this is the
318 case²⁵ and itchy skin in isolation is not a CRS symptom; some asthmatics also avoid
319 NSAIDs on advice from their GP and need a provocation test for confirmation. The self-
320 reported nature of the respiratory sensitivity also renders the subject to recall bias, however
321 other studies have used a similar means of capturing data¹⁷. Despite this, the potential error
322 in recall should be equal across CRS subgroups and controls and therefore should not
323 overly bias the results in any one subgroup. Furthermore, this study focused on a limited
324 number of broad food groups thought to represent foods of moderate to high salicylate
325 content. Future studies using validated food diaries and objective allergy testing are
326 warranted to further investigate the potential role of dietary salicylate in CRS symptom
327 exacerbation.

328 Another limitation is the over-reporting of food sensitivities by the general population. About
329 1-2% of the population have a medically diagnosed food allergy/sensitivity and yet 13%
330 claim to have one²⁶. In our controls 19% said they had a sensitivity, therefore it is possible
331 that the real level of food sensitivity in our groups will probably be much lower than what they
332 self-report. Table 1 also demonstrates the variability in the reported levels of salicylate in
333 food, making categorisation of “high salicylate” foods somewhat problematic.

334 Generalisability

335 Studies of the potential role of dietary salicylates in CRS, such as our study and that carried
336 out by Sommer et al, are hindered by the lack of consensus on the salicylate content of
337 foodstuffs as demonstrated in table 1. The inconsistency in the literature is thought to be the
338 result of methodological variation, along with differences in the variety, growing conditions
339 and preparation of foods analysed²⁷. Further basic science studies are required in order for
340 accurate diet-based studies into the role of dietary salicylates in clinical conditions such as
341 CRS to be carried out in the future.

342 Conclusion

343 This analysis suggests that there is an association between symptom exacerbation in
344 response to food products with higher potential salicylate content, specifically wine, in CRS
345 patients both with and without nasal polyposis when compared to controls, but especially in
346 the CRSwNPs and AFRS phenotypes. Further studies are needed to detail the relationship
347 between dietary intake and CRS subgroups and to determine if this apparent airway
348 sensitivity is specifically a salicylate effect and moreover as to the reality of meaningful
349 dietary modifications. The data present the possibility that a wider group of CRS patients
350 may elicit salicylate sensitivity than those with known N-ERD.

351 Declarations

352 **Ethical approval and consent to participate**

353 The CRES was approved by the Oxford C Research Ethics Committee (Ref: 07/H0606/100), sponsored
354 by the University of East Anglia (UEA).

355 **Consent for publication**

356 Not applicable

357 **Availability of data and material**

358 Not applicable

359 **Funding**

360 The study was funded by the Anthony Long Trust (postage costs) and the Bernice Bibby Trust
361 (research nurse time).

362 **Competing interests**

363 None.

364 **Author contributions**

365 According to the ICMJE authorship criteria:

- 366 1) substantial contributions to conception and design of, or acquisition of data or analysis
367 and interpretation of data
- 368 2) drafting the article or revising it critically for important intellectual content
- 369 3) final approval of the version to be published

370 Carl Philpott 1, 2, 3

371 Rupert Smith 2, 3

372 Cameron Davies-Husband 2, 3

373 Sally Erskine 1, 2, 3

374 Allan Clark 1,2, 3

375 Ailsa Welch 2, 3
376 Claire Hopkins 1, 2, 3
377 Sean Carrie 1, 2, 3
378 Jaydip Ray 1, 2, 3
379 Nirmal Kumar 1, 2, 3
380 Alasdair Robertson 1, 2, 3
381 Shahram Anari 1, 2, 3
382 Naveed Kara 1, 2, 3
383 Vishnu Sunkaraneni 1, 2, 3
384 Robert Almeyda 1, 2, 3
385 Andrew Wilson 2, 3

386

387 **Acknowledgements**

388 The CRES group of Otorhinolaryngologists who recruited patients to the study.
389 Jane Woods, Research Nurse at the James Paget University Hospital for her dedication to
390 the study.

References

- 391 1. Robert-Seilaniantz A, Navarro L, Bari R and Jones JD. Pathological hormone imbalances. *Curr*
392 *Opin Plant Biol.* 2007; 10: 372-9.
- 393 2. Wood A, Baxter G, Thies F, Kyle J and Duthie G. A systematic review of salicylates in foods:
394 estimated daily intake of a Scottish population. *Mol Nutr Food Res.* 2011; 55 Suppl 1: S7-S14.
- 395 3. Szczeklik A and Stevenson DD. Aspirin-induced asthma: advances in pathogenesis, diagnosis,
396 and management. *The Journal of allergy and clinical immunology.* 2003; 111: 913-21; quiz 22.
- 397 4. Samter M and Beers RF, Jr. Intolerance to aspirin. Clinical studies and consideration of its
398 pathogenesis. *Ann Intern Med.* 1968; 68: 975-83.
- 399 5. Stevens WW, Peters AT, Hirsch AG, et al. Clinical Characteristics of Patients with Chronic
400 Rhinosinusitis with Nasal Polyps, Asthma, and Aspirin-Exacerbated Respiratory Disease. *J Allergy Clin*
401 *Immunol Pract.* 2017; 5: 1061-70 e3.
- 402 6. Sommer DD, Rotenberg BW, Sowerby LJ, et al. A novel treatment adjunct for aspirin
403 exacerbated respiratory disease: the low-salicylate diet: a multicenter randomized control crossover
404 trial. *Int Forum Allergy Rhinol.* 2016; 6: 385-91.
- 405 7. Fokkens WJ, Lund VJ, Mullol J, et al. European Position Paper on Rhinosinusitis and Nasal
406 Polyps 2012. *Rhinol Suppl.* 2012; 23: 3 p preceding table of contents, 1-298.
- 407 8. Bent JP, 3rd and Kuhn FA. Diagnosis of allergic fungal sinusitis. *Otolaryngol Head Neck Surg.*
408 1994; 111: 580-8.
- 409 9. Philpott CM, Javer AR and Clark A. Allergic fungal rhinosinusitis - a new staging system.
410 *Rhinology.* 2011; 49: 318-23.
- 411 10. Philpott CM, Erskine S, Hopkins C, et al. Prevalence of asthma, aspirin sensitivity and allergy
412 in chronic rhinosinusitis: data from the UK National Chronic Rhinosinusitis Epidemiology Study.
413 *Respir Res.* 2018; 19: 129.

- 414 11. Philpott C, Erskine S, Hopkins C, et al. A case-control study of medical, psychological and
415 socio-economic factors influencing the severity of chronic rhinosinusitis. *Rhinology*. 2016; 54: 134-
416 40.
- 417 12. Pang YT, Eskici O and Wilson JA. Nasal polyposis: role of subclinical delayed food
418 hypersensitivity. *Otolaryngol Head Neck Surg*. 2000; 122: 298-301.
- 419 13. Al-Qudah M. Food Sensitization in Medically Resistant Chronic Rhinosinusitis with or without
420 Nasal Polyposis. *Int Arch Allergy Immunol*. 2016; 169: 40-4.
- 421 14. Vally H and Misso NL. Adverse reactions to the sulphite additives. *Gastroenterol Hepatol Bed
422 Bench*. 2012; 5: 16-23.
- 423 15. Erskine SE, Notley C, Wilson AM and Philpott CM. Managing chronic rhinosinusitis and
424 respiratory disease: a qualitative study of triggers and interactions. *J Asthma*. 2015; 52: 600-5.
- 425 16. Esmailzadeh H, Esmailzadeh E, Faramarzi M, Nabavi M and Farhadi M. Salicylate Food
426 Intolerance and Aspirin Hypersensitivity in Nasal Polyposis. *Iran J Immunol*. 2017; 14: 81-8.
- 427 17. De Schryver E, Derycke L, Campo P, et al. Alcohol hyper-responsiveness in chronic
428 rhinosinusitis with nasal polyps. *Clin Exp Allergy*. 2017; 47: 245-53.
- 429 18. Kennedy JL, Stoner AN and Borish L. Aspirin-exacerbated respiratory disease: Prevalence,
430 diagnosis, treatment, and considerations for the future. *Am J Rhinol Allergy*. 2016; 30: 407-13.
- 431 19. Hare LG, Woodside JV and Young IS. Dietary salicylates. *J Clin Pathol*. 2003; 56: 649-50.
- 432 20. Picado C, Fernandez-Morata JC, Juan M, et al. Cyclooxygenase-2 mRNA is downexpressed in
433 nasal polyps from aspirin-sensitive asthmatics. *Am J Respir Crit Care Med*. 1999; 160: 291-6.
- 434 21. Mullol J, Fernandez-Morata JC, Roca-Ferrer J, et al. Cyclooxygenase 1 and cyclooxygenase 2
435 expression is abnormally regulated in human nasal polyps. *J Allergy Clin Immunol*. 2002; 109: 824-30.
- 436 22. Roca-Ferrer J, Garcia-Garcia FJ, Pereda J, et al. Reduced expression of COXs and production
437 of prostaglandin E(2) in patients with nasal polyps with or without aspirin-intolerant asthma. *J
438 Allergy Clin Immunol*. 2011; 128: 66-72 e1.
- 439 23. Nayan S, Maby A, Endam LM and Desrosiers M. Dietary modifications for refractory chronic
440 rhinosinusitis? Manipulating diet for the modulation of inflammation. *Am J Rhinol Allergy*. 2015; 29:
441 e170-4.
- 442 24. Woessner KM. Update on Aspirin-Exacerbated Respiratory Disease. *Curr Allergy Asthma Rep*.
443 2017; 17: 2.
- 444 25. Kowalski ML, Agache I, Bavbek S, et al. Diagnosis and management of NSAID-Exacerbated
445 Respiratory Disease (N-ERD)-a EAACI position paper. *Allergy*. 2019; 74: 28-39.
- 446 26. Verrill L, Bruns R and Luccioli S. Prevalence of self reported food allergy in US adults: 2001,
447 2006, and 2010. *Allergy Asthma Proc*. 2015.
- 448 27. Malakar S, Gibson PR, Barrett JS and Muir JG. Naturally occurring dietary salicylates: A closer
449 look at common Australian foods. *J Food Compos Anal*. 2017; 57: 31-9.

Table 1. Salicylate content of selected foods covered by questions included in the questionnaire.

Food groups				Salicylic Acid Content (mg/100g)					
				Malakar et al 2017	Swain et al 1985	Frequency of sensitivity in CRES n (%)			
						Control	CRSs NPs	CRSw NPs	AFRS
Spicy Foods				19 (17.3)	72 (21.4)	85 (21.1)	4 (16)		
	Chilli Powder	-	1.3						
	Curry Powder	-	218						
	Mustard Powder	-	26						
	Paprika	-	203						
	Red Chilli Peppers	0.657	1.2						
	Cumin Powder	60.497	45						
	Black Pepper	4.57	6.2						
Wine*				1 (0.9)	29 (8.6)	74 (18.4)	11 (44.0)		
	White Wine	-	0.1						
	Red Wine	-	0.9						
	Champagne	-	1.02						
Drinks*				2 (1.8)	14 (4.2)	18 (4.2)	0 (0.0)		
	Tea (English Breakfast)	0.24	3						
	Coffee (instant	0.204	0.59						

	Caffeinated)						
	Drinking Chocolate	5.148	-				
	Coca-cola	-	0.25				
Nuts				0 (0.0)	12 (3.6)	17 (4.2)	4 (16.0)
	Almonds	4.709	3				
	Peanuts	-	1.12				
	Cashews	4.11	0.07				
Fruit				1 (0.9)	14 (4.2)	26 (6.5)	3 (12.0)
	Grapes (white)	0.83	-				
	Sultana	-	1.88				
	Dried dates	3.69	4.5				
	Nectarine	1.328	0.49				
	Peach	0.33	0.58				
	Apple (Granny Smith)	0.97	0.59				
	Raspberry	1.052	3.14				
Vegetables				0 (0.0)	3 (0.9)	2 (0.5)	2 (8.0)
	Broccoli	1.101	0.65				
	Green Beans	1.388	0.11				
	Garden Peas	2.552	0.004				
	Tinned Tomato	0.642	0.53				
	Spinach	0.229	0.58				
	Sweet Potato	2.115	0.48				
*Values reported as mg/100ml.							

Table 2. Demographics and selected health characteristics of study population.

Characteristic	Controls (n=110)	CRSwNPs (n=402)	CRSsNPs (n=336)	AFRS (n=25)
Age (years) (SD in brackets)	44 (\pm 14.9)	55 (\pm 14.9)	51 (\pm 15.5)	57 (\pm 14.1)
Female n (%)	71 (64.5)	119 (29.6)	159 (47.3)	15 (60.0)
White British n (%)	95 (86.4)	297 (73.9)	235 (69.9)	22 (88.0)
Asthma n (%)	5 (4.5)	211 (52.5)	73 (21.7)	17 (68.0)
Aspirin Sensitivity n (%)	1 (0.9)	42 (10.4)	10 (3.0)	11 (44.0)
Both above n (%)	0 (0)	40 (9.9)	4 (1.2)	10 (40)
Missing data excluded.				

Table 3. Association between CRS subtype and dietary salicylate sensitivity. The results demonstrate the association in participants who reported sensitivity to one or more of the sub groups of foods.

Group	Total (n)	Dietary Salicylate Sensitivity (%)	Crude OR	95% CI	p value	Adjusted OR*	95% CI	p value
Controls	110	21 (19.1)	1.00			1.00		
CRSwNPs	402	150 (37.3)	2.52	1.50 - 4.23	<0.001	2.56	1.39 - 4.71	0.002
CRSsNPs	336	103 (30.7)	1.87	1.10 - 3.18	0.020	1.86	1.05 - 3.30	0.034
AFRS	25	14 (56.0)	5.39	2.15 - 13.56	<0.001	3.84	1.36 - 10.86	0.011

*Odds ratio adjusted for age, sex, asthma and aspirin sensitivity.

Table 3a. Association between CRS subtype and dietary salicylate sensitivity. The results demonstrate the association in participants who reported sensitivity to one or more of the sub groups of foods excluding individuals who reported yes to having an autoimmune disorder, immunodeficiency or ciliary dysmotility.

Group	Total (n)	Dietary Salicylate Sensitivity (%)	Crude OR	95% CI	p value	Adjusted OR*	95% CI	p value
Controls	109	21 (19.3)	1			1		
CRSwNPs	379	139 (36.7)	1.70	0.99 – 2.90	0.054	1.78	1.00 – 3.19	0.051
CRSsNPs	302	87 (28.8)	2.43	1.44 – 4.08	0.001	2.59	1.40 – 4.80	0.003
AFRS	23	14 (60.9)	6.52	2.49 – 17.08	<0.001	4.90	1.64 – 14.63	0.004

Figure Legends:

Figure 1. Participant flow diagram

Figure 2. Proportion of participants in each group reporting asthma and aspirin sensitivity, and sensitivity to one or more salicylate containing food groups. CRSwNPs = Chronic Rhinosinusitis with nasal polyps; CRSsNPs = Chronic Rhinosinusitis without nasal polyps; AFRS = Allergic Fungal Rhinosinusitis.

Fig. 3. Proportion of control group and CRS subgroups reporting sensitivity/symptom exacerbation. *Pairs statistically significant at $p < 0.008$ (Bonferroni correction). CRSwNPs = Chronic Rhinosinusitis with nasal polyps; CRSsNPs = Chronic Rhinosinusitis without nasal polyps; AFRS = Allergic Fungal Rhinosinusitis.

Appendix 1: Study questionnaire

Ref:

Local Site Ref:

Please try to fill in ALL parts of the questionnaire, even if you do not have sinus problems and do not feel they are directly relevant to you.



CHRONIC RHINOSINUSITIS EPIDEMIOLOGY STUDY (CRES)

FOR DOCTOR TO COMPLETE:

CRS WITHOUT POLYPS	<input type="checkbox"/>	CONFIRMATION OF DIAGNOSIS WITH:
CRS WITH POLYPS	<input type="checkbox"/>	CT SCAN <input type="checkbox"/> ENDOSCOPY <input type="checkbox"/>
CONFIRMED/SUSPECTED AFRS	<input type="checkbox"/>	
CONTROL	<input type="checkbox"/>	

RECRUITMENT SITE

JPUH <input type="checkbox"/>	NNUH <input type="checkbox"/>	WWL <input type="checkbox"/>	SPIRE <input type="checkbox"/>	NGH <input type="checkbox"/>
LDH <input type="checkbox"/>	RSCH <input type="checkbox"/>	GUYS <input type="checkbox"/>	QMC <input type="checkbox"/>	FH <input type="checkbox"/>
CI <input type="checkbox"/>	SRI <input type="checkbox"/>	SGH <input type="checkbox"/>	BCUH <input type="checkbox"/>	RAH <input type="checkbox"/>
IRH <input type="checkbox"/>	HEFT <input type="checkbox"/>	QEH <input type="checkbox"/>	STH <input type="checkbox"/>	WI <input type="checkbox"/>
OUH <input type="checkbox"/>	SAMBU <input type="checkbox"/>	CTHB <input type="checkbox"/>	WHH <input type="checkbox"/>	PHNT <input type="checkbox"/>
RCH <input type="checkbox"/>	RGH <input type="checkbox"/>	AUHNT <input type="checkbox"/>	RBNFT <input type="checkbox"/>	HWPH <input type="checkbox"/>
DBH <input type="checkbox"/>	Other <input type="checkbox"/>	Other, please specify: <input type="text"/>		

Please return the questionnaire to the Norwich Medical School, UEA, Norwich
- for the attention of Mr Carl Philpott



Ref.

How often do you get a cold or sore throat in the space of one year?

Never Seldom Often Frequently

Have you had any previous surgery? Yes No If yes, please specify what and when

Do you have any known confirmed allergies (on a skin prick or blood test)? Yes No
e.g house dust mite

If yes please state

Do you have any suspected allergies? Yes No If yes please state

Have you ever experienced any allergy symptoms such as wheezing, runny nose or itchy skin when taking any of the following?

	Yes	No
Aspirin	<input type="checkbox"/>	<input type="checkbox"/>
Spicy food	<input type="checkbox"/>	<input type="checkbox"/>
Wine	<input type="checkbox"/>	<input type="checkbox"/>
Drinks eg. tea/coffee/fruit juices & cordials	<input type="checkbox"/>	<input type="checkbox"/>
Nuts	<input type="checkbox"/>	<input type="checkbox"/>
Fruits including tomatoes	<input type="checkbox"/>	<input type="checkbox"/>
Vegetables	<input type="checkbox"/>	<input type="checkbox"/>

If yes, please specify

If yes, please specify

If yes, please specify

Do you have any of the following?

	Yes	No
Asthma?	<input type="checkbox"/>	<input type="checkbox"/>
Chronic obstructive airways disease (emphysema or chronic bronchitis)?	<input type="checkbox"/>	<input type="checkbox"/>
Bronchiectasis (disorder where the air passages widen and produce a lot of mucus)?	<input type="checkbox"/>	<input type="checkbox"/>
Diabetes (loss of blood sugar control)?	<input type="checkbox"/>	<input type="checkbox"/>
Immunodeficiency (poor immune response to infections as diagnosed with blood tests)?	<input type="checkbox"/>	<input type="checkbox"/>



Ref.

Do you have any of the following?

- | | Yes | No |
|--|--------------------------|--------------------------|
| Ciliary dysmotility (e.g Cystic Fibrosis, Kartangener's syndrome, Primary Ciliary Dyskinesia)
(disorder where the little hairs on the cells lining the air passages don't work properly)? | <input type="checkbox"/> | <input type="checkbox"/> |
| Hypothyroidism (underactive thyroid gland)? | <input type="checkbox"/> | <input type="checkbox"/> |
| Autoimmune disorder (e.g.systemic lupus erythmatosis, rheumatoid arthritis)? | <input type="checkbox"/> | <input type="checkbox"/> |

Do you have any other medical conditions? Yes No If yes please state

Do you have any regular medications? Yes No If yes please state

Finally, please indicate your Ethnic Group

- WHITE - British
- WHITE - Irish
- WHITE - Other White background*

-
- MIXED - White & Black Caribbean
 - MIXED - White & Black African
 - MIXED - White & Asian
 - MIXED - Other Mixed background*

-
- ASIAN or ASIAN BRITISH - Indian
 - ASIAN or ASIAN BRITISH - Pakistani
 - ASIAN or ASIAN BRITISH - Bangladeshi
 - ASIAN or ASIAN BRITISH - Other Asian background *

-
- BLACK or BLACK BRITISH - Caribbean
 - BLACK or BLACK BRITISH - African
 - BLACK or BLACK BRITISH - Other Black background *

-
- OTHER - Chinese
 - OTHER - Any other group *

* Please state details or country of origin



Figure 1. Participant flow diagram





